Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Maspero

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 19, 2021
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthmaTanya M Laidlaw, Claus Bachert, Nikhil Amin, et al.
The New England Journal of Medicine|October 27, 2021
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe AsthmaMichael E Wechsler, Marcella K Ruddy, Ian D Pavord, et al.
Chest|February 26, 2022
Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE TrialLawrence D Sher, Michael E Wechsler, Klaus F Rabe, et al.
The New England Journal of Medicine|May 22, 2018
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaKlaus F Rabe, Parameswaran Nair, Guy Brusselle, et al.
Journal of Investigational Allergology & Clinical Immunology|June 29, 2026
Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled TrialJorge F Maspero, Anil Gupta, Olaf Schmidt, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 4, 2022
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstructionNicola A Hanania, Mario Castro, Eric Bateman, et al.
The Lancet. Respiratory Medicine|November 13, 2023
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension studyLeonard B Bacharier, Jorge F Maspero, Constance H Katelaris, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 1, 2020
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitisWilliam W Busse, Jorge F Maspero, Yufang Lu, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 28, 2019
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic RhinosinusitisJorge F Maspero, Constance H Katelaris, William W Busse, et al.
The New England Journal of Medicine|December 8, 2021
Dupilumab in Children with Uncontrolled Moderate-to-Severe AsthmaLeonard B Bacharier, Jorge F Maspero, Constance H Katelaris, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 19, 2021
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthmaTanya M Laidlaw, Claus Bachert, Nikhil Amin, et al.
The New England Journal of Medicine|October 27, 2021
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe AsthmaMichael E Wechsler, Marcella K Ruddy, Ian D Pavord, et al.
Chest|February 26, 2022
Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE TrialLawrence D Sher, Michael E Wechsler, Klaus F Rabe, et al.
The New England Journal of Medicine|May 22, 2018
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaKlaus F Rabe, Parameswaran Nair, Guy Brusselle, et al.
Journal of Investigational Allergology & Clinical Immunology|June 29, 2026
Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled TrialJorge F Maspero, Anil Gupta, Olaf Schmidt, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 4, 2022
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstructionNicola A Hanania, Mario Castro, Eric Bateman, et al.
The Lancet. Respiratory Medicine|November 13, 2023
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension studyLeonard B Bacharier, Jorge F Maspero, Constance H Katelaris, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 1, 2020
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitisWilliam W Busse, Jorge F Maspero, Yufang Lu, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 28, 2019
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic RhinosinusitisJorge F Maspero, Constance H Katelaris, William W Busse, et al.
The New England Journal of Medicine|December 8, 2021
Dupilumab in Children with Uncontrolled Moderate-to-Severe AsthmaLeonard B Bacharier, Jorge F Maspero, Constance H Katelaris, et al.
Pageof 6